{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:16:04Z","timestamp":1777497364459,"version":"3.51.4"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Until recently, the treatment landscape for hepatocellular cancer (HCC) was dominated by tyrosine kinase inhibitors (TKIs) which offered an overall survival (OS) benefit when used both in the first-and second-line setting compared to best supportive care. However, the treatment landscape has changed with the introduction of immune checkpoint inhibitors (ICIs) for the treatment of HCC with significant improvement in OS and progression free survival reported with combination atezolizumab and bevacizumab compared to sorafenib in the first-line setting. Nonetheless, the response to ICIs is 20\u201330% and invariably patients will progress. What remains unclear is which therapeutics should be used following ICI exposure. Extrapolating from the evidence base in renal cell carcinoma, subsequent therapy with TKIs offers both a response and survival benefit and are recommended by European guidelines. However, there are a number of novel therapies emerging that target mechanisms of ICI resistance that hold promise both in combination with ICI or as subsequent therapy. This paper will discuss the evidence for ICIs in HCC, the position of second-line therapies following ICIs and research strategies moving forward.<\/jats:p>","DOI":"10.3389\/fimmu.2021.652007","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T06:11:34Z","timestamp":1615788694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Rohini","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Motedayen Aval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Liver","year":"2018","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1499-3872(16)60097-8","article-title":"Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment","volume":"15","author":"Yegin","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab vs. placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3748\/wjg.v25.i24.2977","article-title":"Immunotherapy for hepatocellular carcinoma: current and future","volume":"25","author":"Johnston","year":"2019","journal-title":"World J Gastroenter."},{"key":"B12","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep4.1356","article-title":"Liver macrophages: old dogmas and new insights","volume":"3","author":"Guillot","year":"2019","journal-title":"Hepatol Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1158\/0008-5472.CAN-07-2354","article-title":"Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression","volume":"67","author":"Bunt","year":"2007","journal-title":"Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2012.02.006","article-title":"The three main stumbling blocks for anticancer T cells","volume":"33","author":"Baitsch","year":"2012","journal-title":"Trends Immunol."},{"key":"B18","unstructured":"eUpdate\u2013Hepatocellular Carcinoma Treatment Recommendations2020"},{"key":"B19","first-page":"1","volume-title":"National Cancer Drugs Fund List","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"V874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2020","journal-title":"Ann Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"iv135","DOI":"10.1093\/annonc\/mdz154.026","article-title":"Pembrolizumab (Pembro) therapy vs. best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","volume":"30","author":"Finn","year":"2019","journal-title":"Ann Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.2017.35.15_suppl.4071","article-title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)","volume":"35","author":"Wainberg","year":"2017","journal-title":"J Clin Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2217\/fon-2019-0097","article-title":"RATIONALE 301 study: tislelizumab vs. sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"15","author":"Qin","year":"2019","journal-title":"Future Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.2017.35.15_suppl.4073","article-title":"Phase I\/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses","volume":"35","author":"Kelley","year":"2017","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000489021","article-title":"Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment","volume":"8","author":"Lu","year":"2019","journal-title":"Liver Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study","volume":"37","author":"Llovet","year":"2019","journal-title":"J Clin Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2217\/fon-2020-0283","article-title":"Cabozantinib in combination with atezolizumab vs. sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design","volume":"16","author":"Kelley","year":"2020","journal-title":"Future Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e204930","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol."},{"key":"B43","volume-title":"PB02-04. Clinical Activity of Cabozantinib in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Anti-VEGF and Immuno-Oncology Therapy: Subgroup Analysis From the Phase 3 CELESTIAL trial. Liver Cancer Summit","author":"Abou-Alfa","year":"2020"},{"key":"B44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2019.37.4_suppl.361","article-title":"Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients","volume":"37","author":"Yau","year":"2019","journal-title":"J Clin Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"37","author":"Finn","year":"2018","journal-title":"J Hepatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e000714","DOI":"10.1136\/esmoopen-2020-000714","article-title":"Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","volume":"5","author":"Kelley","year":"2020","journal-title":"ESMO Open."},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000504624","article-title":"Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma","volume":"9","author":"Alsina","year":"2020","journal-title":"Liver Cancer."},{"key":"B48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br J Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated european association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell."},{"key":"B51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: Looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fonc.2019.00308","article-title":"Endothelial cell-derived TGF-beta promotes epithelial-mesenchymal transition via CD133 in HBx-Infected hepatoma cells","volume":"9","author":"Rawal","year":"2019","journal-title":"Front Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/liv.14113","article-title":"Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma","volume":"39","author":"Faivre","year":"2019","journal-title":"Liver Int."},{"key":"B55","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2015.08.021","article-title":"Rationale for anti-OX40 cancer immunotherapy","volume":"52","author":"Aspeslagh","year":"2016","journal-title":"Eur J Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-19-3070","article-title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","volume":"26","author":"Glisson","year":"2020","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.652007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T06:11:37Z","timestamp":1615788697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.652007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2021.652007"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.652007","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"article-number":"652007"}}